ARTL · XBRL financial data

Artelo Biosciences financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (ARTL's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26†Jun 30, 2026
Research and development	1,585	2,124*	1,507	1,685	325	2,476*	1,384	1,871	1,275	893*	773	876
General and administrative	1,029	1,116*	1,082	827	870	1,336*	995	1,279	1,814	1,893*	1,916	1,629
Total operating expenses	2,614	3,240*	2,589	2,512	1,195	3,812*	2,379	3,150	3,089	2,786*	2,689	2,505
Operating income (loss)	(2,614)	(3,240)*	(2,589)	(2,512)	(1,195)	(3,812)*	(2,379)	(3,150)	(3,089)	(2,786)*	(2,689)	(2,505)
Interest expense	0	0*	—	0	0	0*	0	72	111	11*	100	6
Income tax expense (benefit)	0	0*	0	0	0	0*	0	0	0	0*	—	0
Net income (loss)	(2,449)	(3,073)*	(2,483)	(2,433)	(1,132)	(3,778)*	(2,372)	(3,221)	(3,120)	(4,166)*	(2,958)	(2,427)
Earnings per share, diluted USD per share	(0.83)	—	(0.78)	(4.52)	(0.35)	—	(0.72)	(5.61)	(3.97)	—	(4.00)	(0.89)
Weighted average shares, diluted thousands of shares	2,949	—	3,197	538	3,228	—	3,281	574	787	—	739	2,712

† Share count changed about 2x in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (ARTL's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26†Jun 30, 2026
Cash and cash equivalents	2,639	2,815	1,195	881	4,357	2,338	746	2,066	1,720	600	10,273	4,198
Marketable securities	10,225	7,611	6,414	4,721	500	0	0	0	0	—	—	—
Marketable securities, non-current	10,225	7,611	—	—	500	0	—	—	—	—	—	—
Prepaid and other current assets	564	554	579	566	129	219	212	167	107	95	148	173
Total current assets	13,428	10,980	8,188	6,168	4,986	2,557	1,382	2,233	1,827	695	10,421	4,371
Right-of-use asset	29	21	124	116	108	99	91	82	73	64	55	46
Total assets	15,499	13,043	10,354	8,326	7,136	4,698	3,515	4,357	4,267	2,801	12,518	6,459
Accrued liabilities	—	—	—	—	—	0	—	18	46	11	26	0
Total current liabilities	921	1,291	721	940	697	1,772	2,804	5,712	4,860	4,044	5,828	1,455
Lease liability, non-current	—	0	—	—	78	69	59	51	40	29	18	7
Total liabilities	921	1,291	817	1,027	775	1,841	2,863	5,763	4,900	4,073	5,846	1,462
Accumulated deficit	(37,237)	(40,310)	(42,793)	(45,226)	(46,358)	(50,136)	(52,508)	(55,729)	(58,849)	(63,015)	(65,973)	(68,400)
Total stockholders' equity	14,578	11,752	9,537	7,299	6,361	2,857	652	(1,406)	(633)	(1,272)	6,672	4,997
Total liabilities and equity	15,499	13,043	10,354	8,326	7,136	4,698	3,515	4,357	4,267	2,801	12,518	6,459
Common shares outstanding (cover page) thousands of shares	3,189	3,228	3,228	3,228	3,228	3,281	3,281	1,322	2,019	2,125	2,334	4,595

† Share count changed about 2x in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (ARTL's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26†Jun 30, 2026
Net income (loss)	(2,449)	(3,073)*	(2,483)	(2,433)	(1,132)	(3,778)*	(2,372)	(3,221)	(3,120)	(4,166)*	(2,958)	(2,427)
Stock-based compensation	222	219*	213	195	209	201*	192	150	432	368*	401	570*
Net cash from operating activities	(1,802)*	(2,596)*	(2,942)	(2,063)*	(778)*	(2,567)*	(1,597)	(514)*	(3,498)*	(2,911)*	(1,191)	(5,033)*
Net cash from investing activities	(1,832)*	2,741*	1,269	1,750*	4,250*	500*	0	0*	(250)*	188*	—	—
Proceeds from issuing common stock	535*	32*	55	0*	0*	57*	0	1,079*	3,312*	1,760*	10,033	175*
Proceeds from issuing equity	—	—	—	—	—	—	—	—	—	year only	75,000	0*
Net cash from financing activities	535*	32*	55	0*	0*	57*	0	1,816*	3,444*	1,607*	10,860	(1,064)*
Net change in cash	(3,080)*	176*	(1,620)	(314)*	3,476*	(2,019)*	(1,592)	1,320*	(346)*	(1,120)*	9,673	(6,075)*

† Share count changed about 2x in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Artelo Biosciences	4,198	not reported	(5,033)*	4.6M	0.8 quarters	Q2 FY26 10-QJun 30, 2026
Bioxytran	177	not reported	(350)*	114.7M	0.5 quarters	Q2 FY26 10-QJun 30, 2026
Raphael Pharmaceutical	1	not reported	0*	20.2M	—	Q2 FY26 10-QJun 30, 2026
Oncotelic Therapeutics	186	250	(92)*	457.5M	2.0 quarters	Q2 FY26 10-QJun 30, 2026
TherapeuticsMD	9,189	not reported	not reported	11.6M	—	Q2 FY26 10-QJun 30, 2026
Alaunos Therapeutics	124	0	(300)*	2.5M	0.4 quarters	Q2 FY26 10-QJun 30, 2026
BioCardia	4,117	not reported	(1,735)*	15.1M	2.4 quarters	Q2 FY26 10-QJun 30, 2026
Traws Pharma	5,016	not reported	(7,504)*	15.4M	0.7 quarters	Q2 FY26 10-QJun 30, 2026
Mannatech	6,034	26,650	(792)*	1.9M	7.6 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.